All In Biotech

Drug Trial Radar · NCT05245591

Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial

A Randomized, Controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of U101 Oral Capsules in Radiation-induced Cystitis

Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 29, 2022

Primary completion

Nov 1, 2024

Study completion Nov 1, 2029

Sponsor

Lead sponsor
National Taiwan University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
TCM Biotech International Corporation
First posted
Feb 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of pentosan polysulfate sodium versus placebo and in patients with radiation cystitis who have received radiation therapy in pelvic region.

Conditions

  • Radiation Cystitis

Interventions

  • Pentosan Polysulfate Sodium 100 MG Oral CapsuleDrug

    Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks

  • PlaceboDrug

    Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of complete remission in lower urinary tract symptoms and hematuriaTime frame: From date of randomization throughout the treatment period up to 5 years
  2. Time to complete remissionTime frame: From date of randomization to study completion up to 5 years
  3. Time to hematuria recurrenceTime frame: From date of randomization to study completion up to 5 years
  4. Assessment of quality of lifeTime frame: From date of randomization to study completion up to 5 years
  5. Assessment of symptomsTime frame: From date of randomization to study completion up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.